Catalent (CTLT) Cut to “Hold” at ValuEngine

ValuEngine downgraded shares of Catalent (NYSE:CTLT) from a buy rating to a hold rating in a research report released on Tuesday morning.

A number of other research analysts have also weighed in on CTLT. Zacks Investment Research raised Catalent from a hold rating to a buy rating and set a $48.00 price objective on the stock in a report on Monday, July 9th. JPMorgan Chase & Co. increased their price objective on Catalent from $50.00 to $55.00 and gave the company an overweight rating in a report on Wednesday, August 29th. Finally, UBS Group initiated coverage on Catalent in a report on Tuesday, October 9th. They issued a neutral rating and a $48.00 price objective on the stock. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $48.11.

Shares of CTLT stock traded down $0.34 during mid-day trading on Tuesday, reaching $37.31. The stock had a trading volume of 419,750 shares, compared to its average volume of 747,139. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.79 and a current ratio of 2.05. The firm has a market capitalization of $5.24 billion, a PE ratio of 23.47, a P/E/G ratio of 2.15 and a beta of 1.45. Catalent has a 1-year low of $34.24 and a 1-year high of $47.87.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The business had revenue of $551.80 million for the quarter, compared to analyst estimates of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company’s revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.21 earnings per share. Sell-side analysts forecast that Catalent will post 1.72 earnings per share for the current year.

In related news, SVP Lance Miyamoto sold 6,525 shares of the firm’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Barry Littlejohns sold 47,265 shares of the firm’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $41.64, for a total value of $1,968,114.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 184,335 shares of company stock worth $8,161,727. 1.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new stake in Catalent in the second quarter valued at approximately $145,000. Moneta Group Investment Advisors LLC grew its holdings in Catalent by 105.0% in the second quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after purchasing an additional 1,800 shares during the period. CIBC Asset Management Inc acquired a new stake in Catalent in the third quarter valued at approximately $217,000. Hartford Investment Management Co. acquired a new stake in Catalent in the second quarter valued at approximately $220,000. Finally, Rehmann Capital Advisory Group grew its holdings in Catalent by 1,895.9% in the second quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after purchasing an additional 5,043 shares during the period. 92.08% of the stock is currently owned by hedge funds and other institutional investors.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also: Discover Your Risk Tolerance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply